Goldman Sachs
AVNR

Goldman Sachs’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Goldman Sachs’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-27,200
Closed -$461K – 7580
2014
Q4 		$461K Sell
27,200
-424,000
-94% -$5.96M ﹤0.01% 5365
2014
Q3 		$5.38M Buy
451,200
+304,400
+207% +$2.08M ﹤0.01% 2940
2014
Q2 		$828K Sell
146,800
-711,600
-83% -$3.28M ﹤0.01% 4873
2014
Q1 		$3.15M Buy
858,400
+639,400
+292% +$2.44M ﹤0.01% 3547
2013
Q4 		$736K Buy
219,000
+173,900
+386% +$718K ﹤0.01% 5006
2013
Q3 		$191K Sell
45,100
-35,100
-44% -$166K ﹤0.01% 5903
2013
Q2 		$369K Buy
+80,200
New +$276K ﹤0.01% 5181

Goldman Sachs's AVNR Position: Q1 2015 in Review

Goldman Sachs sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 337,576 shares — an estimated $5.72M sold.

Goldman Sachs first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $10.5M in Q3 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Goldman Sachs reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Goldman Sachs sold 337,576 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $5.72M.
  • Goldman Sachs first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • Goldman Sachs's AVANIR PHARMACEUTICALS, INC CL A position peaked at $10.5M in Q3 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Goldman Sachs's 13F filing for Q1 2015, filed 15 May 2015.